Cargando…

Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada

BACKGROUND: There are limited data on outcomes of SARS-CoV-2 infection among infants (<1 year of age). In the absence of approved vaccines for infants, understanding characteristics associated with hospitalization and severe disease from COVID-19 in this age group will help inform clinical manage...

Descripción completa

Detalles Bibliográficos
Autores principales: Piché-Renaud, Pierre-Philippe, Panetta, Luc, Farrar, Daniel S., Moore-Hepburn, Charlotte, Drouin, Olivier, Papenburg, Jesse, Salvadori, Marina I., Laffin, Melanie, Kakkar, Fatima, Morris, Shaun K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401116/
https://www.ncbi.nlm.nih.gov/pubmed/36001553
http://dx.doi.org/10.1371/journal.pone.0272648
_version_ 1784772897908195328
author Piché-Renaud, Pierre-Philippe
Panetta, Luc
Farrar, Daniel S.
Moore-Hepburn, Charlotte
Drouin, Olivier
Papenburg, Jesse
Salvadori, Marina I.
Laffin, Melanie
Kakkar, Fatima
Morris, Shaun K.
author_facet Piché-Renaud, Pierre-Philippe
Panetta, Luc
Farrar, Daniel S.
Moore-Hepburn, Charlotte
Drouin, Olivier
Papenburg, Jesse
Salvadori, Marina I.
Laffin, Melanie
Kakkar, Fatima
Morris, Shaun K.
author_sort Piché-Renaud, Pierre-Philippe
collection PubMed
description BACKGROUND: There are limited data on outcomes of SARS-CoV-2 infection among infants (<1 year of age). In the absence of approved vaccines for infants, understanding characteristics associated with hospitalization and severe disease from COVID-19 in this age group will help inform clinical management and public health interventions. The objective of this study was to describe the clinical manifestations, disease severity, and characteristics associated with hospitalization among infants infected with the initial strains of SARS-CoV-2. METHODS: This is a national, prospective study of infants with SARS-CoV-2 from April 8(th) 2020 to May 31(st) 2021 using the infrastructure of the Canadian Paediatric Surveillance Program. Infants <1 year of age with microbiologically confirmed SARS-CoV-2 infection from both inpatients and outpatients seen in clinics and emergency departments were included. Cases were classified as either: 1) Non-hospitalized patient with SARS-CoV-2 infection; 2) COVID-19-related hospitalization; or 3) non-COVID-19-related hospitalization (e.g., incidentally detected SARS-CoV-2). Case severity was defined as asymptomatic, outpatient care, mild (inpatient care), moderate or severe disease. Multivariable logistic regression was performed to identify characteristics associated with hospitalization. RESULTS: A total of 531 cases were reported, including 332 (62.5%) non-hospitalized and 199 (37.5%) hospitalized infants. Among hospitalized infants, 141 of 199 infants (70.9%) were admitted because of COVID-19-related illness, and 58 (29.1%) were admitted for reasons other than acute COVID-19. Amongst all cases with SARS-CoV-2 infection, the most common presenting symptoms included fever (66.5%), coryza (47.1%), cough (37.3%) and decreased oral intake (25.0%). In our main analysis, infants with a comorbid condition had higher odds of hospitalization compared to infants with no comorbid conditions (aOR = 4.53, 2.06–9.97), and infants <1 month had higher odds of hospitalization then infants aged 1–3 months (aOR = 3.78, 1.97–7.26). In total, 20 infants (3.8%) met criteria for severe disease. CONCLUSIONS: We describe one of the largest cohorts of infants with SARS-CoV-2 infection. Overall, severe COVID-19 in this age group was found to be uncommon. Comorbid conditions and younger age were associated with COVID-19-related hospitalization amongst infants.
format Online
Article
Text
id pubmed-9401116
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-94011162022-08-25 Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada Piché-Renaud, Pierre-Philippe Panetta, Luc Farrar, Daniel S. Moore-Hepburn, Charlotte Drouin, Olivier Papenburg, Jesse Salvadori, Marina I. Laffin, Melanie Kakkar, Fatima Morris, Shaun K. PLoS One Research Article BACKGROUND: There are limited data on outcomes of SARS-CoV-2 infection among infants (<1 year of age). In the absence of approved vaccines for infants, understanding characteristics associated with hospitalization and severe disease from COVID-19 in this age group will help inform clinical management and public health interventions. The objective of this study was to describe the clinical manifestations, disease severity, and characteristics associated with hospitalization among infants infected with the initial strains of SARS-CoV-2. METHODS: This is a national, prospective study of infants with SARS-CoV-2 from April 8(th) 2020 to May 31(st) 2021 using the infrastructure of the Canadian Paediatric Surveillance Program. Infants <1 year of age with microbiologically confirmed SARS-CoV-2 infection from both inpatients and outpatients seen in clinics and emergency departments were included. Cases were classified as either: 1) Non-hospitalized patient with SARS-CoV-2 infection; 2) COVID-19-related hospitalization; or 3) non-COVID-19-related hospitalization (e.g., incidentally detected SARS-CoV-2). Case severity was defined as asymptomatic, outpatient care, mild (inpatient care), moderate or severe disease. Multivariable logistic regression was performed to identify characteristics associated with hospitalization. RESULTS: A total of 531 cases were reported, including 332 (62.5%) non-hospitalized and 199 (37.5%) hospitalized infants. Among hospitalized infants, 141 of 199 infants (70.9%) were admitted because of COVID-19-related illness, and 58 (29.1%) were admitted for reasons other than acute COVID-19. Amongst all cases with SARS-CoV-2 infection, the most common presenting symptoms included fever (66.5%), coryza (47.1%), cough (37.3%) and decreased oral intake (25.0%). In our main analysis, infants with a comorbid condition had higher odds of hospitalization compared to infants with no comorbid conditions (aOR = 4.53, 2.06–9.97), and infants <1 month had higher odds of hospitalization then infants aged 1–3 months (aOR = 3.78, 1.97–7.26). In total, 20 infants (3.8%) met criteria for severe disease. CONCLUSIONS: We describe one of the largest cohorts of infants with SARS-CoV-2 infection. Overall, severe COVID-19 in this age group was found to be uncommon. Comorbid conditions and younger age were associated with COVID-19-related hospitalization amongst infants. Public Library of Science 2022-08-24 /pmc/articles/PMC9401116/ /pubmed/36001553 http://dx.doi.org/10.1371/journal.pone.0272648 Text en © 2022 Piché-Renaud et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Piché-Renaud, Pierre-Philippe
Panetta, Luc
Farrar, Daniel S.
Moore-Hepburn, Charlotte
Drouin, Olivier
Papenburg, Jesse
Salvadori, Marina I.
Laffin, Melanie
Kakkar, Fatima
Morris, Shaun K.
Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada
title Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada
title_full Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada
title_fullStr Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada
title_full_unstemmed Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada
title_short Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada
title_sort clinical manifestations and disease severity of sars-cov-2 infection among infants in canada
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401116/
https://www.ncbi.nlm.nih.gov/pubmed/36001553
http://dx.doi.org/10.1371/journal.pone.0272648
work_keys_str_mv AT picherenaudpierrephilippe clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada
AT panettaluc clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada
AT farrardaniels clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada
AT moorehepburncharlotte clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada
AT drouinolivier clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada
AT papenburgjesse clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada
AT salvadorimarinai clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada
AT laffinmelanie clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada
AT kakkarfatima clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada
AT morrisshaunk clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada
AT clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada